Top-News
Gesundheitswesen USA

Regulus Therapeutics News

Aktie
WKN:  A3DNZ4 ISIN:  US75915K3095 US-Symbol:  RGLS
2,30 €
+0,00 €
0,00%
14.06.24 16:47:22
Handeln Depot/Watchlist
Aktienanzahl *
20,22 Mio.
Marktkapitalisierung *
45,54 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 12.03.2024

Regulus Therapeutics News

04.06.24 - PR Newswire
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire
16.05.24 - PR Newswire
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire
09.05.24 - PR Newswire
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates PR Newswire
06.05.24 - PR Newswire
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney ...
30.04.24 - PR Newswire
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series PR Newswire
21.03.24 - PR Newswire
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates PR Newswire
12.03.24 - PR Newswire
Thinking about buying stock in BigBear.ai, Nukkleus, Singularity Future Technology, Regulus Therapeutics, or ATRenew?
Thinking about buying stock in BigBear.ai, Nukkleus, Singularity Future Technology, Regulus Therapeutics, or ATRenew? PR Newswire
12.03.24 - PR Newswire
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity PR Newswire
12.03.24 - PR Newswire
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the ...
02.01.24 - PR Newswire
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients ...
22.11.23 - PR Newswire
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire
09.11.23 - PR Newswire
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates PR Newswire
02.11.23 - PR Newswire
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal ...
19.10.23 - PR Newswire
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney ...
20.09.23 - PR Newswire
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the ...
13.09.23 - PR Newswire
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients ...
05.09.23 - PR Newswire
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire
23.08.23 - PR Newswire
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023 PR Newswire
08.08.23 - PR Newswire
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates PR Newswire
02.08.23 - PR Newswire
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference PR Newswire

Newssuche

Videos

newspaper
13.06.24 -3,86%
Technical Trading: Zukauf-​Chance bei Top-Trade, wenn
Sugar No.11 Long Typ: Turbo Open End WKN: VV50DP Hebel: 5 Laufzeit: OpenEnd Einstieg: prozyklisch ... Mehr »